Prenetics Global Limited (NASDAQ: PRE) is a Hong Kong-based health sciences company specializing in genomics and diagnostic testing. Founded in 2014 by Danny Yeung and Lawrence Tzang, the company has expanded its presence in the United States and globally. Prenetics focuses on advancing consumer health through science-backed solutions in early detection, prevention, and treatment of diseases, particularly cancer.
Prenetics' consumer initiatives are led by IM8, a health and wellness brand, and CircleDNA, a direct-to-consumer DNA testing platform. CircleDNA utilizes next-generation sequencing technology to provide comprehensive DNA tests, offering insights into health, wellness, and genetic predispositions. The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops genomic profiling panels tailored to meet specific clinical needs.
In June 2025, Prenetics became the first healthcare company to execute an aggressive Bitcoin treasury strategy, securing $20 million in Bitcoin and appointing the former COO of OKEx to its board. The company plans to substantially increase its Bitcoin holdings and aims to become one of the largest healthcare corporate Bitcoin holders. Prenetics also announced plans to accept cryptocurrency payments across its platforms, creating a complete Bitcoin ecosystem from treasury to operations.
Prenetics has gained recognition for its innovative approach to healthcare, combining advanced genomic technologies with strategic financial initiatives. The company's commitment to enhancing life through science positions it as a leader in the evolving health and wellness industry.
